OMERS ADMINISTRATION Corp Sells 71,210 Shares of Cellebrite DI Ltd. (NASDAQ:CLBT)

OMERS ADMINISTRATION Corp lowered its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 61.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 44,850 shares of the company's stock after selling 71,210 shares during the period. OMERS ADMINISTRATION Corp's holdings in Cellebrite DI were worth $988,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the stock. True Wind Capital Management L.P. boosted its stake in shares of Cellebrite DI by 18.2% during the 4th quarter. True Wind Capital Management L.P. now owns 13,861,007 shares of the company's stock valued at $305,358,000 after buying an additional 2,130,386 shares during the period. FMR LLC boosted its stake in shares of Cellebrite DI by 89.1% during the 4th quarter. FMR LLC now owns 10,621,344 shares of the company's stock valued at $233,988,000 after buying an additional 5,004,587 shares during the period. Axon Enterprise Inc. acquired a new stake in shares of Cellebrite DI during the 4th quarter valued at $198,270,000. Voss Capital LP boosted its stake in shares of Cellebrite DI by 1.2% during the 4th quarter. Voss Capital LP now owns 3,240,000 shares of the company's stock valued at $71,377,000 after buying an additional 39,700 shares during the period. Finally, Pertento Partners LLP boosted its stake in shares of Cellebrite DI by 26.7% during the 4th quarter. Pertento Partners LLP now owns 2,975,374 shares of the company's stock valued at $65,547,000 after buying an additional 626,373 shares during the period. Institutional investors and hedge funds own 45.88% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. reduced their price objective on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a research note on Monday, May 12th. Needham & Company LLC reduced their price objective on shares of Cellebrite DI from $28.00 to $24.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Finally, Lake Street Capital lifted their price objective on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a research note on Friday, February 14th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Cellebrite DI has an average rating of "Buy" and a consensus target price of $22.43.

Cellebrite DI Price Performance

Shares of CLBT stock traded up $0.50 on Friday, hitting $17.21. The company's stock had a trading volume of 1,554,679 shares, compared to its average volume of 1,465,922. The stock has a market capitalization of $4.12 billion, a price-to-earnings ratio of -12.38, a P/E/G ratio of 4.27 and a beta of 1.44. Cellebrite DI Ltd. has a fifty-two week low of $10.25 and a fifty-two week high of $26.30. The firm's fifty day moving average price is $18.91 and its 200-day moving average price is $20.18.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of $0.09 by $0.01. The firm had revenue of $107.55 million for the quarter, compared to the consensus estimate of $109.36 million. Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. The business's quarterly revenue was up 20.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.08 EPS. Analysts predict that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.